Arsanis, Inc. Appoints Michael P. Gray As Chief Financial Officer And Chief Business Officer

WALTHAM, Mass. & VIENNA, Austria--(BUSINESS WIRE)--Arsanis, Inc., a clinical-stage biopharmaceutical company focused on monoclonal antibody approaches for the prevention and treatment of serious infectious diseases, today announced that Michael P. Gray has joined the company as chief financial officer and chief business officer.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.